Higher expression of IFIT3, but not other IFITs, in HCC tissues predicted better response to IFN-α therapy, potentially through STAT1/2 augmentation of IFN-α effector signaling [34]. The gene discussed is IFNA1; the disease is hepatocellular carcinoma.